Biotechnology

Vaximm appoints Sébastien Wieckowski as CSO, leveraging his data science expertise to advance its oral cancer vaccine platform at a pivotal clinical stage.

Profusa launches its Lumee system for research, aiming to capture a piece of the $47B CRO market and revolutionize drug development with real-time data.

A new partnership aims to revolutionize chronic care by letting patients self-administer large-volume biologics safely in their own homes.

Results in Nature Medicine reveal an immunotherapy that may stop cancer before it starts in high-risk Lynch Syndrome carriers, heralding a new era of prevention.

In a strategic move to enhance domestic drug production, Agno Pharma has acquired a key Oregon manufacturing site, signaling major industry consolidation.

With a new $16.5M loan, Ocular Science is poised to expand its role in compounded eye medications, meeting the needs of an aging population.

Backed by Canada's life sciences engine adMare, new biotech firm Ocythera is advancing a unique non-retinoid therapy for debilitating bone disorders.

With its lead drug in human trials, ViroMissile hires a seasoned CBO to navigate the competitive oncolytic virus market and secure its future.

With the appointment of agency veteran Raffi Siyahian, VaultBio aims to bridge the gap between life sciences strategy and real-world market execution.

A new partnership aims to make life-saving cancer and anti-infective drugs stable at room temperature, revolutionizing global access and sustainability.

Merck's former R&D IT head Matt Studney joins TetraScience, a move highlighting biopharma's critical pivot from fragmented data to industrial-scale AI.

The Korean biopharma giant is leveraging its biosimilar success to fund a major push into cutting-edge cancer therapies and advanced drug platforms.

Flashpoint Therapeutics appoints an FDA-approved drug developer as CSO, a strategic move to accelerate its groundbreaking structural nanomedicine platform.

Reimbursements are falling and costs are rising, but top allergy practices are boosting revenue by 22%. A new report reveals their data-driven secrets.

From developing neonatal ventilators to pivotal COVID vaccine research, a San Antonio institute marks 85 years on the front lines of global health.

MIT economist Andrew Lo joins the Global Coalition for Adaptive Research, bringing Wall Street strategies to revolutionize clinical trials for rare diseases.

A new alliance in healthcare marketing merges pharmaceutical expertise with provider-side insights, leveraging AI and big data to fix a fragmented system.

With its lead cancer therapy pelareorep showing promise, Oncolytics hires veteran execs to navigate the final hurdles of clinical trials and regulatory approval.

Adial Pharmaceuticals files a key patent to protect its personalized Alcohol Use Disorder drug, AD04, until 2045, signaling a new era for addiction medicine.

With a promising brain injury drug and no approved rivals, Oragenics heads to a tax-haven investor summit to secure funding for its next critical phase.